(150) Sustained Release Implant Delivery of BDNF Upregulating Oligonucleotide in Parkinson’s Disease

Introduction: Research has shown that BDNF promotes dopaminergic activity and enhances motor function in animal models of Parkinson's disease. However, direct delivery of exogenous BDNF to CNS is difficult due to its low bioavailability. Our group has developed the trans-nasal route of Minimally Invasive Nasal Depot (MIND) for CNS delivery overcoming the limitations of BBB penetration and traditional nasal administration. In the current study, we have utilized MIND approach to sustain BDNF-upregulating oligonucleotide delivery using an osmotic core-shell implant in a rat model of Parkinson’s disease (PD).